Craig H. Barratt, director, Intuitive Surgical, sells $510,370 in stock

Craig H. Barratt, a director at Intuitive Surgical Inc. (NASDAQ:ISRG), sold shares totaling $510,370 on October 23, 2026, according to a recent SEC filing. The transaction involved the disposition of 1,150 shares of common stock at a price of $443.80 per share.

The sale followed Mr. Barratt’s exercise of non-qualified stock options on the same day. The transaction comes as Intuitive Surgical, a prominent player in the Healthcare Equipment & Supplies industry according to InvestingPro, trades near its Fair Value of $449 with a market capitalization of $155.84 billion. Despite the director’s sale, the company maintains a "GREAT" financial health score and has posted revenue growth of over 20% in the last twelve months. He acquired 1,150 shares of common stock through the exercise at a price of $90.4944 per share, totaling $104,068. These options were granted pursuant to the Non-Employee Directors’ Stock Option Plan and vested 100% one year after the grant date or at the next Shareholders Meeting.

Both the option exercise and the subsequent sale were conducted in accordance with a Rule 10b5-1 trading plan, which is set to expire on March 15, 2027. Following these transactions, Mr. Barratt directly holds no shares of common stock, while an additional 27,948 shares are held indirectly by a trust.

In other recent news, Intuitive Surgical reported third-quarter revenue of $3.05 billion, surpassing both Oppenheimer’s estimate of $2.92 billion and the consensus expectation of $2.91 billion. However, the company’s GAAP earnings per share fell short of expectations, coming in at $1.49 due to a $450 million litigation settlement. Despite this, the company exceeded overall earnings estimates by $0.35 per share, driven by strong performance across its Systems, Services, and Instruments & Accessories segments. Notably, Systems revenue reached $769 million, surpassing the Street’s estimate of $679 million.

In terms of analyst actions, RBC Capital lowered its price target for Intuitive Surgical to $550 from $575, citing concerns over U.S. volume growth. Mizuho also reduced its target to $400 from $415, maintaining a Neutral rating due to a slowdown in procedure growth. On a positive note, Truist Securities reiterated a Buy rating with a $510 target, highlighting a 40% growth in net da Vinci placements in the third quarter. Stifel also maintained a Buy rating and a $550 price target following the company’s third-quarter results. Oppenheimer reiterated an Outperform rating with a $500 target, noting the company’s performance exceeded revenue expectations.